Amicus Therapeutics, Inc. (FOLD)

NASDAQ: FOLD · IEX Real-Time Price · USD
10.78
+0.18 (1.70%)
Jun 29, 2022 4:00 PM EDT - Market closed

Company Description

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.

Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.

It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development.

The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Amicus Therapeutics, Inc.
Amicus Therapeutics Logo
Country United States
Founded 2002
IPO Date May 31, 2007
Industry Biotechnology
Sector Health Care
Employees 496
CEO John Crowley

Contact Details

Address:
1 Cedarbrook Dr
Cranbury, New Jersey 08512-3618
United States
Phone 215 921 7600
Website amicusrx.com

Stock Details

Ticker Symbol FOLD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001178879
CUSIP Number 03152W109
ISIN Number US03152W1099
Employer ID 71-0869350
SIC Code 2834

Key Executives

Name Position
John F. Crowley Chairman and Chief Executive Officer
Bradley L. Campbell M.B.A. President, Chief Operating Officer and Director
Daphne E. Quimi CPA Chief Financial Officer
Ellen S. Rosenberg Chief Legal Officer and Corporate Secretary
David M. Clark Chief People Officer
Samantha Prout Vice President, Global Controller and Principal Accounting Officer
Andrew Faughnan Senior Director of Investor Relations
Patrik S. Florencio Senior Vice President, Global Chief Compliance and Risk Officer
Diana Moore Head of Global Corporate Communications
Jayne C. Gershkowitz Chief Patient Advocate

Latest SEC Filings

Date Type Title
Jun 17, 2022 4 Statement of changes in beneficial ownership of securities
Jun 10, 2022 S-8 Securities to be offered to employees in employee benefit plans
Jun 10, 2022 4 Statement of changes in beneficial ownership of securities
Jun 10, 2022 4 Statement of changes in beneficial ownership of securities
Jun 10, 2022 4 Statement of changes in beneficial ownership of securities
Jun 10, 2022 4 Statement of changes in beneficial ownership of securities
Jun 10, 2022 4 Statement of changes in beneficial ownership of securities
Jun 10, 2022 4 Statement of changes in beneficial ownership of securities
Jun 10, 2022 4 Statement of changes in beneficial ownership of securities
Jun 10, 2022 4 Statement of changes in beneficial ownership of securities